OPKO Health (OPK) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
OPKO Announces Second Quarter Operating and Financial Results
August 5, 2015 4:00 PM EDTAnnounced the Acquisition of Bio-Reference Laboratories; Closing Anticipated by the End of August Acquired EirGen Pharma, A Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer RayaldeeTM New Drug Application (NDA) Submission Accepted by FDA; Expected PDUFA date of March 29, 2016 Completed the Enrollment in hGH-CTP Phase 3 Trial in Growth Hormone Deficient Adults New Pre-Clinical Data Supporting Subcutaneous Administration for Long Acting Factor VIIa-CTP for Hemophilia; Phase 2a Clinical Trial Expected to Commence in Q3 2015... More
